3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
44
Triple Negative Breast Neoplasms
20
Breast Neoplasms
16
Carcinoma, Non-Small-Cell Lung
14
Neoplasm Metastasis
10
Lung Neoplasms
10
Squamous Cell Carcinoma of Head and Neck
8
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Neoplasms
6
Adenocarcinoma
6
Cholangiocarcinoma
5
Stomach Neoplasms
4
Gallbladder Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Esophageal Neoplasms
4
Biliary Tract Neoplasms
4
Uterine Cervical Neoplasms
3
Recurrence
3
Pancreatic Adenocarcinoma
3
Ovarian Neoplasms
3
Head and Neck Neoplasms
3
Fallopian Tube Neoplasms
3
Endometrial Neoplasms
3
Colorectal Neoplasms
3
Small Cell Lung Carcinoma
2
Sarcoma
2
Rectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Pancreatic Ductal
2
Carcinoma, Hepatocellular
2
Interventions
trifluridine tipiracil drug combination
1
reolysin
1
atezolizumab
1
Gemcitabine
1
Albumin-Bound Paclitaxel
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Anal Cancer Metastatic
×
Albumin-Bound Paclitaxel
×
1 year
×
Clear all
NCT07280377
2026-05-19
GOBLET
Oncolytics Biotech
Phase 1/2
Active not recruiting
122 enrolled